Navigation Links
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Date:11/8/2007

mg twice daily and Gleevec 800 mg (400 mg twice daily) in 150 patients with chronic-phase CML resistant to prior Gleevec doses of 400 or 600 mg. For patients receiving SPRYCEL, at 12 weeks 36 percent achieved a major cytogenetic response, the study's primary endpoint (29 percent with Gleevec), and 22 percent achieved a complete cytogenetic response (8 percent with Gleevec). With longer treatment and follow-up, 52 percent achieved a major cytogenetic response (33 percent with Gleevec), and 40 percent of patients achieved a complete cytogenetic response (16 percent with Gleevec). The rate of major cytogenetic response with SPRYCEL was lower among patients aged 65 years and over.

At the time of analysis, 39 of 49 patients receiving Gleevec had crossed over to SPRYCEL; 15 of 101 patients receiving SPRYCEL had crossed over to Gleevec. Crossover to alternate therapy was permitted in the event of disease progression or intolerable toxicity. Median duration of treatment prior to crossover was 14 months for SPRYCEL and three months for Gleevec.

Incidence of selected adverse reactions (all grades) in the Phase 2 randomized study in patients receiving SPRYCEL 70 mg twice daily or Gleevec 800 mg daily (400 mg twice daily) included diarrhea (37%, 29%); fluid retention events (36%, 43%) such as pleural effusion (23%, 0%), superficial edema (17%, 41%), generalized edema (2%, 4%), congestive heart failure/cardiac dysfunction (2%, 0%), pericardial effusion (1%, 0%), pulmonary edema (3%, 0%), pulmonary hypertension (1%, 0%); nausea (24%, 33%); hemorrhage (18%, 8%) including gastrointestinal bleeding (3%, 0%), and vomiting (10%, 24%).

In this same study, the frequency of Grade 3/4 neutropenia, thrombocytopenia, and anemia was 63%, 56%, and 19%, respectively, in the SPRYCEL group and 39%, 14%, and 8%, respectively, in the Gleevec group. The frequency of Grade 3/4 hypocalcemia was 4% in the SPRYCEL group and 0% in the Gleevec group.

Patients enrolled in this stu
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
3. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
4. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
7. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
11. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/6cg3zw/cell_therapy ) ... report "Cell Therapy - Technologies, Markets and ... report describes and evaluates cell therapy technologies and ... important role in the practice of medicine. Hematopoietic ... bone marrow transplants. Role of cells in drug ...
(Date:5/28/2015)... May 28, 2015 DryLet, LLC ... in applications such as animal waste reduction, bioremediation, ... reduction in wastewater treatment plants and restaurant kitchen ... World Pork Expo, June 3-5 in Des Moines, ... in a Wall Street Journal article because of ...
(Date:5/28/2015)... Md. , May 28, 2015  GenVec, Inc. ... and CEO, Douglas J. Swirsky , will present ... Conference at 11 a.m. EDT on Thursday, June 4, ... of Mr. Swirsky,s presentation will be available at the ... be available on GenVec,s website.  To access, visit ...
(Date:5/28/2015)... 2015 Global futurist and keynote ... ask his audiences if they are ready for ... solar cells, fuel cells, rapid health care diagnostic ... storage technology, driverless cars, artificial intelligence masquerading as ... online education. , While the majority of ...
Breaking Biology Technology:Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2DryLet to Showcase Patented ManureMagic™ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2GenVec To Present At The Jefferies Healthcare Conference 2Futurist Jack Uldrich to Deliver 4 Keynote Addresses in June 2
... THOUSAND OAKS, Calif., Dec. 6, 2011 Amgen (NASDAQ: ... and Drug Administration (FDA) has modified the requirements of ... Program. Prescribing physicians, patients and institutions are no longer ... the Nplate® NEXUS (Network of EXperts Understanding and Supporting ...
... GAITHERSBURG, Md., Dec. 6, 2011 GenVec, Inc. (Nasdaq: ... achieved the second milestone in its collaboration with Novartis ... of treatments for hearing loss and balance disorders. The ... preclinical development activities. "Completing this milestone ...
... elegant design, University at Buffalo chemists have synthesized tiny, ... purify nanomaterials. , Sculpted from a special kind of ... tiny, organic tubes whose interior walls carry a negative ... only positively charged particles. , In addition, because UB ...
Cached Biology Technology:Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy 2Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy 3Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy 4Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy 5Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy 6Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy 7Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy 8GenVec Achieves Second Milestone in Collaboration 2GenVec Achieves Second Milestone in Collaboration 3Chemists become molecular sculptors, synthesizing tiny, molecular traps 2Chemists become molecular sculptors, synthesizing tiny, molecular traps 3
(Date:5/14/2015)... YORK , May 14, 2015 /PRNewswire/ ... in identity verification and online remote proctoring, ... a software-as-a-service (SaaS) company and creator of ... customers of the two companies will benefit ... in Canvas. As a fully ...
(Date:5/11/2015)... Ohio , May 11, 2015  Through a well-rounded ... Ohio had a strong showing at AUVSI,s Unmanned ... These representatives of Ohio,s UAS industry ... and abroad from all points along the UAS ecosystem. ... Development Coalition,s (DDC) Vice President for Aerospace Rich Knoll ...
(Date:5/10/2015)... May 11, 2015 Fingerprint Cards (FPC) ... and FPC1155 from the distributor World Peace Industrial Group (WPI), ... in Asia . Deliveries are planned to ... used by smartphone manufacturers in China . ... communicated revenue guidance of + 1 000 MSEK for 2015.   ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... 2012 /PRNewswire-iReach/ -- Global Information Inc is pleased ... new research tool for cancer drug research and development companies ... Drug targets and their pathways are the ... of cancer. The Oncology Drug Pathway Analyzer from BioSeeker Group ...
... Two studies appearing in the ,current issue of ... http://www.ingentaconnect.com/content/cog/ct/ , evaluate the transplantation potential and success ... to a clinical study that reports the occurrence of ... cultured islets , A team of researchers from ...
... Richardson, Ph.D., Assistant Professor, Department of Microbiology & Immunology, ... been honored with one of two 2012 Merck Irving ... two young scientists to recognize and award excellence in ... presented in memory of Irving S. Sigal, an instrumental ...
Cached Biology News:New Tool Helps Drug Developers Optimize Their Research and Target Development for Better Results and a Stronger Competitive Edge 2New Tool Helps Drug Developers Optimize Their Research and Target Development for Better Results and a Stronger Competitive Edge 3Some factors that impact islet transplantation explored in Cell Transplantation papers 2Some factors that impact islet transplantation explored in Cell Transplantation papers 3Some factors that impact islet transplantation explored in Cell Transplantation papers 4The American Society for Microbiology honors Anthony R. Richardson 2
...
Use as the souce of CETP enzyme for screening CETP inhibitors. Use in conjunction with the CETP activity assay kit (K601-100)....
For mRNA Differential Display with three one-base anchored oligo-dT primers and rationally designed arbitrary 13mers. These kits feature the latest generation of isotopic mRNA Differential Display t...
22 x 50 mm; No. 1 thickness range: 0.13 to 0.17 mm, suitable for work in histology, cytology, urinalysis and microbiology, precleaned, store at room temperature ...
Biology Products: